Bioxytran (OTCMKTS:BIXT) is a biotechnology and nutraceutical company focused on the development and commercialization of proprietary compounds for metabolic disorders and related conditions. Founded in 2011 and headquartered in Jupiter, Florida, the company combines pharmaceutical research with nutraceutical formulation to create novel oral therapies. Bioxytran’s mission is to address key areas of unmet medical need, particularly obesity, type 2 diabetes and nonalcoholic fatty liver disease (NAFLD), by leveraging its patented L-TUG drug delivery technology.
The company’s lead clinical candidate, BXT-100, is an oral formulation designed to regulate fat absorption and improve glucose metabolism through a novel mechanism of action that targets key enzymes in lipid processing. Preclinical studies have demonstrated BXT-100’s potential to reduce weight gain and lower blood glucose in animal models, supporting plans for first-in-human trials. In parallel, Bioxytran markets a line of dietary supplements under its trade name, offering consumers products aimed at supporting healthy weight management and metabolic wellness. These products are distributed through e-commerce platforms and select retail partners in the United States, Canada and Europe.
Bioxytran’s research and development efforts are supported by collaborations with academic institutions and contract research organizations, while manufacturing is conducted under cGMP conditions at third-party facilities. The company holds multiple patents covering its L-TUG delivery system and associated compositions. Bioxytran has also forged strategic partnerships to advance regulatory submissions and expand its global footprint, with ongoing initiatives targeting markets in Asia and Latin America.
The management team is led by Chief Executive Officer Stephen L. Yiu, who brings over two decades of experience in pharmaceutical R&D and product commercialization. Chief Scientific Officer Dr. Richard S. Henderson oversees Bioxytran’s discovery programs, while Chief Financial Officer Robert C. Shapiro manages corporate finance and investor relations. Together, the leadership team is steering the company toward clinical milestones and potential commercialization of its first therapeutic candidates.
